SOURCE Frost & Sullivan
Focus on disease prevention coupled with an anticipated rise in the number of elderly people will aid market development
SAO PAULO, Feb. 19, 2014 /PRNewswire/ -- Investments in healthcare by the government to prevent diseases and promote health is fuelling the uptake of in vitro diagnosis (IVD) reagent kits in Brazil. The popularity of evidence-based medicine and the pressure to reduce costs in the Brazilian healthcare system are reinforcing this trend. To further strengthen the healthcare industry, the government has implemented incentive programs that encourage local manufacture of IVD equipment and reagent kits and reduce the country's dependence on imported products.
New research from Frost & Sullivan (http://www.lifesciences.frost.com), Analysis of the Brazilian Market for Reagent Kits in In Vitro Diagnosis, finds that the market earned revenues of $1.01 billion in 2012 and estimates this to reach $1.52 billion in 2017. The research covers the immunochemistry, microbiology, hematology/hemostasis, molecular diagnosis, urinalysis, and point-of-care testing (POCT) application segments. Although POCT accounted for only one percent of the total market share in 2012, the segment is expected to develop considerably over the forecast period.
"The increase of investments by the Brazilian Federal Government in the healthcare area, the growing cohort of elderly people and healthcare concerns are widening the potential of the market for reagent kits in IVD in Brazil," said Frost & Sullivan Healthcare Senior Industry Analyst Israel Nena. "The number of aged people is expected to go up from the current 23.5 million to nearly 63 million in 2050."
However, the host of taxes levied on reagent kits in IVD is increasing the price of these products, in turn, hindering uptake. Taxes alone can account for 70-100 percent of the invoice price, on top of which freight, insurance and import duties are added.
The market is also being challenged by new legislation (resolution 25/2010), which requires all IVD manufacturing plants to receive the good manufacturing practices certification. This is delaying the approval of reagent kits and equipment as the regulatory authority lacks sufficient personnel to inspect manufacturing sites within a reasonable timeframe.
In addition, the diagnosis laboratories market is witnessing consolidation. The three largest clinical laboratories – DASA Diagnostic Laboratory Group, Grupo Fleury and Hermes Pardini – held a combined market share of 30 percent in 2012. With these companies looking to participate in more mergers and acquisitions, the price erosion of IVD products will continue. Pressure exerted by the public sector through purchase bids will aggravate the drop in product prices.
"To remain competitive, Brazilian IVD companies need to obtain the technology to manufacture reagent kits with a higher value such as markers for tumors and molecular biology tests," noted Nena. "Some Brazilian companies have already signed partnership agreements with foreign IVD companies."
In fact, the market is being shaped by the recent interest of foreign companies to enter the Brazilian market for reagent kits in IVD to cater to promising but underdeveloped segments such as molecular diagnosis and POCT.
If you are interested in more information on this research, please send an email to Francesca Valente, Corporate Communications, at email@example.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
Analysis of the Brazilian Market for Reagent Kits in In Vitro Diagnosis is part of the Life Sciences Growth Partnership Service program. Frost & Sullivan's related research services include: Global Tissue Diagnostics Market, Global Next Generation Sequencing Informatics Market, and MicroRNA Tools and Services Market. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Analysis of the Brazilian Market for Reagent Kits in In Vitro Diagnosis
Corporate Communications – Latin America
P: +54 11 4777 5300
F: +54 11 4777 5300
©2012 PR Newswire. All Rights Reserved.